Compare
Cue Biopharma, Inc. vs Celularity Inc vs Foghorn Therapeutics Inc. vs Alumis Inc.
| Latest fiscal year | Cue Biopharma, Inc. CUE | Celularity Inc CELU | Foghorn Therapeutics Inc. FHTX | Alumis Inc. ALMS |
|---|---|---|---|---|
| Year ended | 2025-12-31 | 2025-12-31 | 2025-12-31 | 2025-12-31 |
| Revenue | $27.47M | $26.55M | $30.91M | $24.05M |
| Revenue growth (YoY) | +195.7% | -51.0% | +36.8% | n/a |
| Gross margin | n/a | 24.4% (computed) | n/a | n/a |
| Operating margin | -96.7% | -230.9% | -279.5% | n/m |
| Net margin | -96.9% | -345.4% | -240.3% | n/m |
| Net income | -$26.60M | -$91.72M | -$74.28M | -$243.32M |
| EPS (Diluted) | -$0.28 | -$3.59 | -$1.18 | -$2.86 |
| Operating cash flow | -$21.69M | -$13.25M | -$86.10M | -$369.52M |
| Free cash flow | -$21.86M | n/a | -$86.15M | -$370.18M |
| Cash & equivalents | $27.14M | $6.17M | $80.88M | $89.67M |
| Total assets | $42.21M | $107.33M | $198.10M | $411.94M |
| Total liabilities | $15.78M | $145.39M | $306.60M | $110.64M |
| Shareholders' equity | $26.43M | -$38.06M | -$108.50M | $301.30M |
| Return on year-end equity | -100.6% | n/a | n/a | -80.8% |
| Shares outstanding | 96.62M | 28.84M | 56.66M | n/a |
Revenue, most recent five fiscal years
| Fiscal year | Cue Biopharma, Inc. | Celularity Inc | Foghorn Therapeutics Inc. | Alumis Inc. |
|---|---|---|---|---|
| Latest | $27.47M Ended 2025-12-31 | $26.55M Ended 2025-12-31 | $30.91M Ended 2025-12-31 | $24.05M Ended 2025-12-31 |
| 1 year earlier | $9.29M Ended 2024-12-31 | $54.22M Ended 2024-12-31 | $22.60M Ended 2024-12-31 | n/a |
| 2 years earlier | $5.49M Ended 2023-12-31 | $22.77M Ended 2023-12-31 | $34.16M Ended 2023-12-31 | n/a |
| 3 years earlier | $1.25M Ended 2022-12-31 | $17.98M Ended 2022-12-31 | $19.23M Ended 2022-12-31 | n/a |
| 4 years earlier | $14.94M Ended 2021-12-31 | $21.34M Ended 2021-12-31 | $1.32M Ended 2021-12-31 | n/a |